Jpmorgan Chase & CO Immunic, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMUX
# of Institutions
68Shares Held
57.6MCall Options Held
600Put Options Held
254K-
Avidity Partners Management LP Dallas, TX8.9MShares$10.2 Million0.45% of portfolio
-
Bvf Inc San Francisco, CA8.9MShares$10.2 Million0.35% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$8.39 Million0.79% of portfolio
-
Janus Henderson Group PLC London, X06.99MShares$8.04 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$6.43 Million0.01% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $35.1M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...